Mecide Gharibo, Vice President, Head of Hematology Global Medical Affairs at Bristol Myers Squibb, shared a post by Hayder Saeed, Director, Medical Engagement Lead at Bristol Myers Squibb, on LinkedIn, adding:
“Well said Dr Hayder Saeed and ASH25 delivered another great congress that left all of us energized and hopeful on behalf of patients across the hematology portfolio. Very excited with the data disclosures with both of our myeloma and lymphoma celmod agents currently in phase 3 programs and the data from the phase I BCL6 ligand directed degrader! I am deeply grateful to our BMS medical matrix teams for an outstanding ASH and look forward to a very productive 2026!”
Quoting Hayder Saeed‘s post:
“I’m feeling energized after ASH25, where we shared new data across multiple targeted protein degradation modalities, including CELMoD agents and ligand-directed degraders.
Our presence at the meeting, and everything we learned from our colleagues on-site, leaves me feeling hopeful in our ability to translate innovation into meaningful therapies for patients who need them most.
Some of my key takeaways from the meeting:
There’s a lot of momentum building around CELMoD agents
I was especially encouraged by the early readouts from our ligand-directed degraders
Explore the latest hematology research at Bristol Myers Squibb.”
Proceed to the video attached to the post.
More posts featuring ASH25 on OncoDaily.